Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

0567437 - ÚI 2024 RIV NL eng J - Článek v odborném periodiku
Gampenrieder, S. - Dezentje, V. - Lambertini, M. - de Nonneville, A. - Marhold, M. - Le Du, F. - Cortés Salgado, A. - Alpuim Costa, D. - Vaz Batista, M. - Chic Ruché, N. - Tinchon, C. - Petzer, A. - Blondeaux, E. - Del Mastro, L. - Targato, G. - Bertucci, F. - Gonçalves, A. - Viret, F. - Bartsch, R. - Mannsbart, C. - Deleuze, A. - Robert, L. - Saavedra Serrano, C. - Gion Cortés, M. - Sampaio-Alves, M. - Vitorino, M. - Pecen, Ladislav - Singer, C. - Harbeck, N.
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group.
ESMO OPEN. Roč. 8, č. 1 (2023), č. článku 100747. E-ISSN 2059-7029
Institucionální podpora: RVO:67985807
Klíčová slova: triple-negative breast cancer * metastatic * HER2-low * OS * real-world data * prognosis
Obor OECD: Oncology
Impakt faktor: 7.3, rok: 2022
Způsob publikování: Open access
https://dx.doi.org/10.1016/j.esmoop.2022.100747

BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan–Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models.
RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265, 29.8%) and primary tumors (n = 425, 33.4%, P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00, 95% CI 0.83-1.19, P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95, 95% CI 0.79-1.13, P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89, 95% CI 0.69-1.17, P = 0.414). CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
Trvalý link: https://hdl.handle.net/11104/0338693